search
Back to results

Transpulmonary Thermodilution Measurements in Patients With Heart Diseases

Primary Purpose

Heart Diseases

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
PiCCO Catheter (Pulsiocath 5F)
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Heart Diseases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Coronary heart disease without impaired left ventricular function [LV-EF > 50%] (n=10, control group)
  • Coronary heart disease with impaired left ventricular function [LV-EF < 50%] (n=10)
  • Dilated cardiomyopathy (n=10),
  • Aortic valve stenosis (n=10),
  • Mitral valve regurgitation (n=10),
  • Diastolic left ventricular dysfunction (n=10) and
  • Right heart failure (n=10)

Exclusion criteria:

  • Patients with catecholamine dependent cardiogenic shock, severe respiratory distress because of pulmonary oedema, intubated patients, patients with atrial fibrillation, atrioventricular conduction abnormalities, and slow ventricular tachycardia will not be included.
  • Moreover patients not being able to give informed consent are excluded. Even more, pregnant women are excluded from the study due to the radiation exposure in line with heart catheterization. A pregnancy test will be performed prior to participating with this study.
  • The age does not represent an exclusion criterion.

Sites / Locations

  • Medical Intensive Care Unit, University Hospital of Zurich

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

LV-EF > 50%

Arm Description

PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]

Outcomes

Primary Outcome Measures

Cardiac Output, Preload values (GEDV)
Outcome measure is obtained during PiCCO measurement and left/right heart catherization, respectively ("point-of-care" measurement). There is no follow-up examination thereafter.

Secondary Outcome Measures

Full Information

First Posted
October 2, 2009
Last Updated
June 25, 2015
Sponsor
University of Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT02035007
Brief Title
Transpulmonary Thermodilution Measurements in Patients With Heart Diseases
Official Title
Transpulmonary Thermodilution Measurements in Patients With Heart Diseases
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to examine the validation of the PiCCO (Pulse Contour Cardiac Output)-derived transpulmonary thermodilution technology in patients with heart diseases.
Detailed Description
How do PiCCO and PAC (pulmonary artery catheter) derived hemodynamic variables change in different cardiac pathologies? How do PiCCO hemodynamic variables compare to transthoracic echocardiographic parameters in different cardiac pathologies? How does GEDV (global enddiastolic volume) correlate with left ventricles end-diastolic volume (LVEDV) assessed by LV (left ventricle) ventriculography and echocardiography? How do PiCCO cardiac function variables (GEF [global ejection fraction]; CFI [cardiac function index]) correlate with LV dP/dt max, LVEF (left ventricular ejection fraction) assessed by LV ventriculography and echocardiography, LVFAC (left ventricular fractional area of change), LV stroke work index (LVSWI) and cardiac power (CP)? How does GEDV compare to LVEDV and left ventricular end-diastolic pressure (LVEDP) as assessed by the pulmonary artery occlusion pressure (PAOP)? How does right ventricular function influence GEDV, GEF and CFI?

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Diseases

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LV-EF > 50%
Arm Type
Experimental
Arm Description
PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]
Intervention Type
Device
Intervention Name(s)
PiCCO Catheter (Pulsiocath 5F)
Other Intervention Name(s)
Pulsiocath 5F, Pulsion Medical Systems, Munich, Germany
Intervention Description
Measuring of PiCCO derived values
Primary Outcome Measure Information:
Title
Cardiac Output, Preload values (GEDV)
Description
Outcome measure is obtained during PiCCO measurement and left/right heart catherization, respectively ("point-of-care" measurement). There is no follow-up examination thereafter.
Time Frame
Day 1 only

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Coronary heart disease without impaired left ventricular function [LV-EF > 50%] (n=10, control group) Coronary heart disease with impaired left ventricular function [LV-EF < 50%] (n=10) Dilated cardiomyopathy (n=10), Aortic valve stenosis (n=10), Mitral valve regurgitation (n=10), Diastolic left ventricular dysfunction (n=10) and Right heart failure (n=10) Exclusion criteria: Patients with catecholamine dependent cardiogenic shock, severe respiratory distress because of pulmonary oedema, intubated patients, patients with atrial fibrillation, atrioventricular conduction abnormalities, and slow ventricular tachycardia will not be included. Moreover patients not being able to give informed consent are excluded. Even more, pregnant women are excluded from the study due to the radiation exposure in line with heart catheterization. A pregnancy test will be performed prior to participating with this study. The age does not represent an exclusion criterion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marco Maggiorini, Prof MD
Organizational Affiliation
University Hospital Zurich, Medical Intensive Care Unit
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Intensive Care Unit, University Hospital of Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Transpulmonary Thermodilution Measurements in Patients With Heart Diseases

We'll reach out to this number within 24 hrs